AstraZeneca CFO Sarin on Earnings, Covid, M&A Pipeline

The transcript discusses AstraZeneca's strong quarterly performance, highlighting growth in oncology and cardiovascular sectors, and the acquisition of Alexion. The company emphasizes innovation, spending significantly on R&D, and achieving notable success with a new oncology drug. COVID-19 treatments and vaccines have saved millions of lives, with a focus on immunocompromised patients. The strong dollar impacts earnings, while China's market faces challenges due to pricing policies. AstraZeneca maintains a robust pipeline and focuses on cost management and supply chain resilience.

What was the growth percentage for AstraZeneca's oncology sector in the recent quarter?

• 15%

• 19%

• 30%

• 22%

How much did AstraZeneca spend on R&D in the recent quarter?

• $1.5 billion

• $3 billion

• $2.4 billion

• $2 billion

What is the name of AstraZeneca's innovative COVID-19 therapy?

• Covaxin

• Evoshield

• Remdesivir

• Vaxzevria

What impact has the strong dollar had on AstraZeneca's earnings?

• No impact

• Single-digit impact

• Double-digit impact

• Triple-digit impact

What is the expected trend for AstraZeneca's business in China this year?

• Stable growth

• Triple-digit decline

• Single-digit decline

• Double-digit growth

What is AstraZeneca's approach to managing rising distribution costs?

• Increasing prices

• Long-term contracts and dual sourcing

• Outsourcing logistics

• Reducing workforce

What is AstraZeneca's strategy for acquisitions?

• Focus on internal innovation only

• Avoid acquisitions

• Acquire companies in unrelated fields

• Balance internal and external innovation